Gregory Ostrow, MD, joins Jennifer Galvin, MD, to discuss his entrepreneurism in pediatric ophthalmology and the starting of Sydnexis, a clinical-stage biopharmaceutical company he founded. He describes the journey to discovering a way to neutralize and stabilize compounded atropine eye drops to effectively treat myopia in pediatric patients. He also shares information from the STAR study, a phase 3 clinical trial evaluating the company’s patented formulation of low-dose atropine for myopia control.